Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company N30 Pharma has signed a licensing agreement with NitroMed covering the respiratory use of an s-nitrosothiol drug candidate. Financial terms of the deal have not been disclosed.
Subscribe to our email newsletter
S-nitrosothiols are endogenous molecules that store and transduce nitric oxide, and are critical modulators of airway and vascular smooth muscle tone.
Charles Scoggin, chairman of N30 Pharma, said: “I am extremely pleased to announce this agreement. NitroMed is a leader in exploring the medical utility of nitric oxide and s-nitrosothiol therapies, and has foundational intellectual property in the area.”